Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: Results from the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial

Marino Labinaz, Rakhi Kilaru, Karen Pieper, Steven P. Marso, Michael M. Kitt, Maarten L. Simoons, Robert M. Califf, Eric J. Topol, Paul W. Armstrong, Robert A. Harrington

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background - Patients with prior CABG with a subsequent non-ST-segment elevation acute coronary syndrome (ACS) pose an increasingly important clinical problem. Although GP IIb/IIIa inhibitors have improved the outcome of patients with ACS, their efficacy in patients with prior CABG has not been previously evaluated. Methods and Results - We analyzed the 30- and 180-day outcomes of patients with prior CABG enrolled in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. In this trial, which evaluated the efficacy of eptifibatide in patients with ACS, 1134 patients (12%) with prior CABG and 8321 without prior CABG were enrolled. After adjusting for differences in baseline characteristics and treatment, patients with prior CABG had a significantly higher mortality rates at 30 days (hazard ratio [HR], 1.45 [95% CI, 1.06 to 1.98]; P=0.019) and at 180 days (HR, 1.32 [95% CI, 1.04 to 1.67]; P=0.021). At 30 days, there was a similar effect on the primary end point of death or myocardial infarction in the eptifibatide group versus the placebo group in prior CABG patients (unadjusted HR, 0.90 [95% CI, 0.67 to 1.20]) and in patients without a history of CABG (unadjusted HR, 0.89 [95% CI, 0.80 to 0.99]). Conclusions - Patients with prior CABG with non-ST-segment elevation ACS have a significantly worse prognosis than do patients without a history of CABG. The treatment effect of eptifibatide in the prior CABG group was similar to the effect seen in patients without prior CABG.

Original languageEnglish (US)
Pages (from-to)322-327
Number of pages6
JournalCirculation
Volume105
Issue number3
DOIs
StatePublished - Jan 22 2002

Fingerprint

Integrin beta3
Platelet Glycoprotein GPIIb-IIIa Complex
Unstable Angina
Acute Coronary Syndrome
Coronary Artery Bypass
Therapeutics
eptifibatide
Platelet Membrane Glycoprotein IIb

Keywords

  • Bypass
  • Coronary disease
  • Glycoproteins
  • Platelets

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting : Results from the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial. / Labinaz, Marino; Kilaru, Rakhi; Pieper, Karen; Marso, Steven P.; Kitt, Michael M.; Simoons, Maarten L.; Califf, Robert M.; Topol, Eric J.; Armstrong, Paul W.; Harrington, Robert A.

In: Circulation, Vol. 105, No. 3, 22.01.2002, p. 322-327.

Research output: Contribution to journalArticle

Labinaz, Marino ; Kilaru, Rakhi ; Pieper, Karen ; Marso, Steven P. ; Kitt, Michael M. ; Simoons, Maarten L. ; Califf, Robert M. ; Topol, Eric J. ; Armstrong, Paul W. ; Harrington, Robert A. / Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting : Results from the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial. In: Circulation. 2002 ; Vol. 105, No. 3. pp. 322-327.
@article{a0017f14fd7046acb8095dbf6758fb77,
title = "Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: Results from the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial",
abstract = "Background - Patients with prior CABG with a subsequent non-ST-segment elevation acute coronary syndrome (ACS) pose an increasingly important clinical problem. Although GP IIb/IIIa inhibitors have improved the outcome of patients with ACS, their efficacy in patients with prior CABG has not been previously evaluated. Methods and Results - We analyzed the 30- and 180-day outcomes of patients with prior CABG enrolled in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. In this trial, which evaluated the efficacy of eptifibatide in patients with ACS, 1134 patients (12{\%}) with prior CABG and 8321 without prior CABG were enrolled. After adjusting for differences in baseline characteristics and treatment, patients with prior CABG had a significantly higher mortality rates at 30 days (hazard ratio [HR], 1.45 [95{\%} CI, 1.06 to 1.98]; P=0.019) and at 180 days (HR, 1.32 [95{\%} CI, 1.04 to 1.67]; P=0.021). At 30 days, there was a similar effect on the primary end point of death or myocardial infarction in the eptifibatide group versus the placebo group in prior CABG patients (unadjusted HR, 0.90 [95{\%} CI, 0.67 to 1.20]) and in patients without a history of CABG (unadjusted HR, 0.89 [95{\%} CI, 0.80 to 0.99]). Conclusions - Patients with prior CABG with non-ST-segment elevation ACS have a significantly worse prognosis than do patients without a history of CABG. The treatment effect of eptifibatide in the prior CABG group was similar to the effect seen in patients without prior CABG.",
keywords = "Bypass, Coronary disease, Glycoproteins, Platelets",
author = "Marino Labinaz and Rakhi Kilaru and Karen Pieper and Marso, {Steven P.} and Kitt, {Michael M.} and Simoons, {Maarten L.} and Califf, {Robert M.} and Topol, {Eric J.} and Armstrong, {Paul W.} and Harrington, {Robert A.}",
year = "2002",
month = "1",
day = "22",
doi = "10.1161/hc0302.102578",
language = "English (US)",
volume = "105",
pages = "322--327",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting

T2 - Results from the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial

AU - Labinaz, Marino

AU - Kilaru, Rakhi

AU - Pieper, Karen

AU - Marso, Steven P.

AU - Kitt, Michael M.

AU - Simoons, Maarten L.

AU - Califf, Robert M.

AU - Topol, Eric J.

AU - Armstrong, Paul W.

AU - Harrington, Robert A.

PY - 2002/1/22

Y1 - 2002/1/22

N2 - Background - Patients with prior CABG with a subsequent non-ST-segment elevation acute coronary syndrome (ACS) pose an increasingly important clinical problem. Although GP IIb/IIIa inhibitors have improved the outcome of patients with ACS, their efficacy in patients with prior CABG has not been previously evaluated. Methods and Results - We analyzed the 30- and 180-day outcomes of patients with prior CABG enrolled in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. In this trial, which evaluated the efficacy of eptifibatide in patients with ACS, 1134 patients (12%) with prior CABG and 8321 without prior CABG were enrolled. After adjusting for differences in baseline characteristics and treatment, patients with prior CABG had a significantly higher mortality rates at 30 days (hazard ratio [HR], 1.45 [95% CI, 1.06 to 1.98]; P=0.019) and at 180 days (HR, 1.32 [95% CI, 1.04 to 1.67]; P=0.021). At 30 days, there was a similar effect on the primary end point of death or myocardial infarction in the eptifibatide group versus the placebo group in prior CABG patients (unadjusted HR, 0.90 [95% CI, 0.67 to 1.20]) and in patients without a history of CABG (unadjusted HR, 0.89 [95% CI, 0.80 to 0.99]). Conclusions - Patients with prior CABG with non-ST-segment elevation ACS have a significantly worse prognosis than do patients without a history of CABG. The treatment effect of eptifibatide in the prior CABG group was similar to the effect seen in patients without prior CABG.

AB - Background - Patients with prior CABG with a subsequent non-ST-segment elevation acute coronary syndrome (ACS) pose an increasingly important clinical problem. Although GP IIb/IIIa inhibitors have improved the outcome of patients with ACS, their efficacy in patients with prior CABG has not been previously evaluated. Methods and Results - We analyzed the 30- and 180-day outcomes of patients with prior CABG enrolled in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. In this trial, which evaluated the efficacy of eptifibatide in patients with ACS, 1134 patients (12%) with prior CABG and 8321 without prior CABG were enrolled. After adjusting for differences in baseline characteristics and treatment, patients with prior CABG had a significantly higher mortality rates at 30 days (hazard ratio [HR], 1.45 [95% CI, 1.06 to 1.98]; P=0.019) and at 180 days (HR, 1.32 [95% CI, 1.04 to 1.67]; P=0.021). At 30 days, there was a similar effect on the primary end point of death or myocardial infarction in the eptifibatide group versus the placebo group in prior CABG patients (unadjusted HR, 0.90 [95% CI, 0.67 to 1.20]) and in patients without a history of CABG (unadjusted HR, 0.89 [95% CI, 0.80 to 0.99]). Conclusions - Patients with prior CABG with non-ST-segment elevation ACS have a significantly worse prognosis than do patients without a history of CABG. The treatment effect of eptifibatide in the prior CABG group was similar to the effect seen in patients without prior CABG.

KW - Bypass

KW - Coronary disease

KW - Glycoproteins

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=0037154323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037154323&partnerID=8YFLogxK

U2 - 10.1161/hc0302.102578

DO - 10.1161/hc0302.102578

M3 - Article

C2 - 11804987

AN - SCOPUS:0037154323

VL - 105

SP - 322

EP - 327

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 3

ER -